Triple-Negative Breast Cancer

Oncology
7
Pipeline Programs
6
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 6 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
2 programs
2
IMMU-132 infusion is administered to participants in one arm for the studyPhase 21 trial
IMMU-132 infusion is administered to participants in one arm for the studyPhase 2
Active Trials
NCT02161679Withdrawn0Est. Aug 2016
Chipscreen Biosciences
Chipscreen BiosciencesChina - Shenzhen
1 program
1
ChiauranibPhase 2Small Molecule1 trial
Active Trials
NCT05336721TerminatedEst. Nov 2024
Alliance Pharmaceuticals
1 program
1
brostallicinPhase 21 trial
Active Trials
NCT01091454Completed48Est. Nov 2014
Bristol Myers Squibb
1 program
1
RomidepsinPhase 1/21 trial
Active Trials
NCT02393794Active Not Recruiting51Est. Jul 2026
AN
Adlai NortyeNORTH BRUNSWICK, NJ
1 program
1
AN0025Phase 1
Curis
CurisMA - Lexington
1 program
1
CUDC-907Phase 11 trial
Active Trials
NCT02307240CompletedEst. May 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Chipscreen BiosciencesChiauranib
Gilead SciencesIMMU-132 infusion is administered to participants in one arm for the study
Alliance Pharmaceuticalsbrostallicin
Bristol Myers SquibbRomidepsin
CurisCUDC-907

Clinical Trials (5)

Total enrollment: 99 patients across 5 trials

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Start: Nov 2021Est. completion: Nov 2024
Phase 2Terminated
NCT02161679Gilead SciencesIMMU-132 infusion is administered to participants in one arm for the study

Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer

Start: Aug 2016Est. completion: Aug 20160
Phase 2Withdrawn

Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer

Start: Jun 2010Est. completion: Nov 201448 patients
Phase 2Completed

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Start: Jul 2015Est. completion: Jul 202651 patients
Phase 1/2Active Not Recruiting

Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

Start: Nov 2014Est. completion: May 2019
Phase 1Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

6 companies competing in this space